| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 09 Nov 2026 | 10-Q |
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition
Biologics License Application (“BLA”) Submission for Tralesinidase Alfa Enzyme Replacement Therapy (“TA-ERT”) for the Treatment of MPS IIIB Remains on Track for December 2026 Amended Avenue Loan Agreement to Increase Tranche 2 Availabili... |
| 14 Aug 2026 | SCHEDULE 13G |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G |
| 12 Aug 2026 | 10-Q |
| 12 Aug 2026 |
8-K: Results of Operations and Financial Condition
Biologics License Application (BLA) for TA-ERT for the Treatment of MPS IIIB Anticipated in the Fourth Quarter of 2026 TrAnsform Confirmatory Study Required for Potential FDA Accelerated Approval of TA-ERT Expected to Initiate in the Fou... |
| 04 Aug 2026 | SCHEDULE 13G/A |
| 30 Jul 2026 | SCHEDULE 13G |
| 29 Jul 2026 |
Form 4: Quartel Adrian W, Chief Medical Officer
Granted 13,000 Restricted Stock Units |
| 29 Jul 2026 |
Form 3: Quartel Adrian W, Chief Medical Officer
No securities owned |
| 27 Jul 2026 | SCHEDULE 13G |
| 27 Jul 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On July 27, 2026, Spruce Biosciences, Inc. (the “Company”) appointed Adrian Quartel, M.D., FFPM, as the Company’s Chief Medical Officer, replacing Dr. Kirk Ways, who had been serving as the Company’s Interim Chief Medical Officer. Dr. Wa... |
| 09 Jul 2026 |
Form 4: Szwarcberg Javier B., Director
Received 266 shares as a grant or award ($1.21K) |
| 26 May 2026 |
Form 4: Spiegelman Daniel K, Director
Granted 1,700 Stock Option (Right to Buy) |
| 26 May 2026 |
Form 4: Simpson Camilla V, Director
Granted 1,700 Stock Option (Right to Buy) |
| 26 May 2026 |
Form 4: Grey Michael G, Director
Granted 1,700 Stock Option (Right to Buy) |
| 26 May 2026 |
Form 4: Barretto-Ko Percival, Director
Granted 1,700 Stock Option (Right to Buy) |
Loading...